<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM IMMULOGIC
PHARMACEUTICAL CORPORATION FORM 10-Q FOR THE PERIOD ENDING JUNE 30, 2000 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q FOR THE PERIOD ENDING
JUNE 30, 2000.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
<CURRENCY> U.S. $

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             APR-01-2000
<PERIOD-END>                               JUN-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                          10,452
<SECURITIES>                                     5,070
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                19,670
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  19,670
<CURRENT-LIABILITIES>                            1,084
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           208
<OTHER-SE>                                      18,380
<TOTAL-LIABILITY-AND-EQUITY>                    19,670
<SALES>                                              0<F1>
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0
<FN>
<F1>COMPANY IS IN LIQUIDATION AND ALL FINANCIAL STATEMENTS HAVE BEEN PREPARED BASED
ON LIQUIDATION BASIS ACCOUNTING.
</FN>


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission